Follow on Google News News By Tag Industry News * Pharmaceutical * More Industries... News By Place Country(s) Industry News
Follow on Google News | GlaxoSmithKline and Rosa Present Psoriasis Collaboration Results at International IRA ConferencePhysioPD™ modeling collaboration in psoriasis to be presented September 9-13, 2012.
By: Rosa & Co The presentation will describe the development and use of a custom-designed Psoriasis PhysioMap® which provided information and methodology to enable key decisions in early development target prioritization. The map was built using literature data and then critically reviewed by R&D scientists and disease experts. The presentation will show how the map was used to evaluate the roles of drug targets in disease pathways, their potential interactions, and their relative contributions to efficacy potential. This process has informed the selection and prioritization of drug development targets, and it set the stage for development of a quantitative PhysioPD model that will further elucidate and prioritize target potential. "We are pleased to share the initial results from our ongoing collaboration with GSK”, said Dr. Rebecca Baillie, Chief Scientist, PhysioPD at Rosa. “The results of this collaboration show the business value and scientific usefulness of developing a Psoriasis PhysioMap. The PhysioMap development process was critical for establishing a common understanding of the key data and material uncertainties relevant to psoriasis and providing a framework to facilitate cross-functional communication within GSK.” About Rosa Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|